STOCK TITAN

Medpace Holdings Inc - MEDP STOCK NEWS

Welcome to our dedicated news page for Medpace Holdings (Ticker: MEDP), a resource for investors and traders seeking the latest updates and insights on Medpace Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Medpace Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Medpace Holdings's position in the market.

Rhea-AI Summary
Medpace Holdings, Inc. (MEDP) reported strong financial results for the fourth quarter and full year of 2023, with revenue increasing 26.5% and 29.2% respectively. Net new business awards grew by 26.7% in Q4 2023. The company's GAAP net income for Q4 2023 was $78.3 million, with an EBITDA of $95.8 million. For the full year 2023, GAAP net income was $282.8 million, and EBITDA was $362.5 million. Medpace provided a positive financial guidance for 2024, forecasting revenue growth of 14.0% to 16.7% and EBITDA in the range of $400.0 million to $430.0 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.3%
Tags
earnings
-
Rhea-AI Summary
Medpace Holdings, Inc. (Nasdaq: MEDP) will report its Q4 and fiscal year 2023 financial results on February 12, 2024, followed by a conference call on February 13, 2024, at 9:00 a.m. ET. Interested parties can register in advance to participate in the call and access the webcast via the company's website. A slide presentation will also be available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.1%
Tags
conferences earnings
-
Rhea-AI Summary
Medpace Holdings, Inc. (Nasdaq: MEDP) announced financial results for Q3 2023. Revenue increased 28.3% to $492.5 million compared to the prior-year period. Net new business awards were $611.5 million, resulting in a net book-to-bill ratio of 1.24x. GAAP net income was $70.6 million, or $2.22 per diluted share. EBITDA was $90.2 million, with an EBITDA margin of 18.3%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.67%
Tags
earnings
Rhea-AI Summary
Medpace Holdings, Inc. will report Q3 2023 financial results on October 23, 2023. Conference call scheduled for October 24, 2023 at 9:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.91%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.22%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.12%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
conferences earnings
Medpace Holdings Inc

Nasdaq:MEDP

MEDP Rankings

MEDP Stock Data

11.82B
24.29M
20.95%
83.71%
3.54%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Cincinnati

About MEDP

a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.